Positive results for Catabasis’ DMD drug

Published Date
Beatriz Bustillo Ramirez
Orange box stating: Breaking news research

Catabasis has shared new data supporting edasalonexent as a potential treatment for Duchenne muscular dystrophy. In the Phase 2 MoveDMD trial and open-label extension study, boys with Duchenne  treated with edasalonexent had similar growth to unaffected boys in the same age range. This is good news, as many boys with Duchenne experience stunted growth due to steroids.

For further information, please read Catabasis’ press release and newsletter.

If you have any questions about this news story or any other DMD research, please contact the MDUK Research Line on 020 7803 4813 or email research@musculardystrophyuk.org.

Keep in touch